Inclusion Criteria:

- CRPC with up to 2 prior chemotherapy regimens

- Progressive disease on CT, MRI or bone scan per mRECIST

- Has recovered to baseline/CTCAE less than or equal to Grade 1 from toxicities related
to prior treatment (except alopecia)

- Agree to use accepted barrier method of contraception

Exclusion Criteria:

- Cytotoxic chemotherapy within 3 weeks

- Prior treatment with cabozantinib or other c-MET inhibitor

- Prior therapy with a lyase inhibitor

- Concurrent use of hormonal therapies other than LHRH analogue or orchiectomy

- Received radiation therapy to thoracic cavity or GI tract within 3 months, to bone or
brain metastasis within 2 weeks or to any other site within 4 weeks of first dose of
study drug

- Prior treatment with a small molecular kinase inhibitor within 2 weeks of study entry

- Received another investigational product within 28 days prior to study entry

- Active brain metastases or epidural disease

- Requires concomitant treatment in therapeutic doses with warfarin or warfarin-related
agents

- No uncontrolled significant intercurrent or recent illness